Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
NewcelX ( (NCEL) ) has issued an announcement.
On December 11, 2025, NewcelX Ltd. announced the publication of a patent application in China for a new class of compounds, DOXA, aimed at treating neurological diseases. This development is a significant step in expanding NewcelX’s intellectual property portfolio and supports its strategy to advance therapeutic innovation in neurology and metabolic diseases. The patent covers compounds with potential applications in CNS-related conditions, including narcolepsy, and aligns with NewcelX’s broader efforts in regenerative medicine and CNS drug development. The publication also lays the groundwork for future registration in Hong Kong, enhancing protection in a key market.
More about NewcelX
NewcelX is a global biotechnology company specializing in cell engineering, regenerative medicine, and neurological disorders. The company leverages an integrated platform that combines advanced stem-cell technologies with neuroscience expertise to develop a diversified pipeline targeting conditions such as ALS, Type 1 Diabetes, and other CNS-related disorders. Headquartered in Zurich, Switzerland, NewcelX also conducts R&D operations in Israel.
Average Trading Volume: 200,493
Technical Sentiment Signal: Sell
Current Market Cap: $20.74M
For detailed information about NCEL stock, go to TipRanks’ Stock Analysis page.